{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:28:41Z","timestamp":1771014521426,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":9214,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scandinavian Journal of Haematology"],"published-print":{"date-parts":[[1984,2]]},"abstract":"<jats:p>Pentostatin (2\u2032\u2010deoxycoformycin, DCF) was administered to 17 patients with a variety of lymphoid neoplasms, both T\u2010 and B\u2010cell, that were refractory to conventional treatments. Several responses and 2 complete remissions occurred. Toxic effects were less severe than previously described: this may be attributable to relatively low doses of DCF or to precautions taken to prevent tumour lysis syndrome. DCF appears valuable as a second\u2010line treatment in non\u2010Hodgkin's lymphomas and as initial treatment in T\u2010cell chronic lymphocytic leukaemia and mycosis fungoides. Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF. The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1984.tb02167.x","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:08:14Z","timestamp":1280966894000},"page":"130-134","source":"Crossref","is-referenced-by-count":36,"title":["Effectiveness of Pentostatin (2\u2018\u2010Deoxycoformycin) in Refractory Lymphoid Neoplasms"],"prefix":"10.1111","volume":"32","author":[{"given":"A. S. D.","family":"Spiers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Ruckdeschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(82)90023-7"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108334"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109179"},{"key":"e_1_2_1_5_2","first-page":"3343","article-title":"Phase I study of \u2018\u2010deoxycoformycin in acute lymphoblastic leukemia","volume":"41","author":"Poplack DG","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90060-4"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91491-4"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V57.3.406.406","article-title":"The biochemical and clinical consequences of 2\u2032\u2010deoxycoformycin in refractory lymphoproliferative malignancy","volume":"57","author":"Grever MR","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_9_2","first-page":"153","article-title":"T\u2010cell chronic leukemia (T\u2010CLL) with unique cell phenotype, intradermal bleeding, and dramatic response to deoxycoformycin","volume":"58","author":"Spiers ASD","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_10_2","first-page":"487","article-title":"Deoxycoformycin in the treatment of refractory chronic lymphocytic leukemia","volume":"22","author":"Grever MR","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_11_2","first-page":"163a","article-title":"Effectiveness of pentostatin (2\u2032\u2010deoxycoformycin, DCF) in refractory lymphoid neoplasms","volume":"60","author":"Spiers ASD","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V58.1.91.91","article-title":"Clinical pharmacology of deoxycoformycin","volume":"58","author":"Major PP","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_13_2","first-page":"221","article-title":"2\u2032\u2010deoxycoformycin toxicity correlates with red cell dATP\/ATP ratios","volume":"22","author":"Koller CA","year":"1981","journal-title":"Proc Am Ass Cancer Res"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"}],"container-title":["Scandinavian Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1984.tb02167.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1984.tb02167.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:15:03Z","timestamp":1697804103000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1984.tb02167.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1984,2]]}},"alternative-id":["10.1111\/j.1600-0609.1984.tb02167.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1984.tb02167.x","archive":["Portico"],"relation":{},"ISSN":["0036-553X"],"issn-type":[{"value":"0036-553X","type":"print"}],"subject":[],"published":{"date-parts":[[1984,2]]}}}